Reference number(s)
6032-A

Specialty Guideline Management Elevidys

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Elevidys	delandistrogene moxeparvovec-rokl

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Elevidys is indicated in individuals at least 4 years of age:

- For the treatment of Duchenne muscular dystrophy (DMD) in patients who are ambulatory and have a confirmed mutation in the DMD gene.
- For the treatment of DMD in patients who are non-ambulatory and have a confirmed mutation in the DMD gene.

The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of Elevidys microdystrophin. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

All other indications are considered experimental/investigational and not medically necessary.

Reference number(s)
6032-A

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Genetic test results confirming the DMD diagnosis.
- Medical records (e.g., chart notes and/or laboratory reports) documenting ambulation status.

Exclusions

- Coverage will not be provided for members with a deletion in exon 8 and/or exon 9 in the DMD gene.

Coverage Criteria

Duchenne Muscular Dystrophy

Authorization of 3 months for one dose total may be granted for treatment of Duchenne muscular dystrophy when all of the following criteria are met:

- Member has a diagnosis of DMD with a confirmed mutation in the DMD gene
- Member is ambulatory.
- Member is 4 through 5 years of age (at least 4 years 0 days and less than 6 years old)
- Member has anti-recombinant adeno-associated virus serotype rh74 (anti-AAVrh74) total binding antibody titers of < 1:400.
- Member does not currently have an active infection.
- Member does not have significant liver dysfunction or disease, defined as at least one of the following:
    - Preexisting liver impairment; or
    - Chronic hepatic condition; or
    - Acute liver disease (e.g., acute hepatic viral infection)

References

1. Elevidys [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; August 2024.
2. ClinicalTrials.gov. NCT03769116. A randomized, double-blind placebo-controlled study of delandistrogene moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy. Accessed May 9, 2025.

3. Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023 Nov;94(5):955-968.